Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal

Completed

• Conditions: Hypercholesterolemia

• Registration Number: NCT00240344
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-09
• Study First Submitted: 2005-10-16
• Study First Submitted QC: 2005-10-16
• Study First Posted: 2005-10-18
• Primary Completion: 2008-02
• Study Completion: 2008-02
• Status Verified: 2011-08
• Last Update Submitted: 2011-08-29
• Last Update Posted: 2011-08-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2650

Inclusion Criteria

• High risk patients
• High doses of other statins
• LDL-C known, starts with Crestor 10 mg
• Permission to use patient data by AstraZeneca (AZ)

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Research Site; 🇳🇱 Zwolle, Netherlands